- Home
- GLUE
GLUE
Monte Rosa Therapeutics Inc.
as 03-28-2025 4:00pm EST
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $14.33 | AVG Volume (30 days): | 809.6K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.21 - $12.40 | Next Earning Date: | 03-20-2025 |
| Revenue: | $75,622,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -79.43% | Revenue Growth (next year): | 2.30% |
Stock Insider Trading Activity of Monte Rosa Therapeutics Inc. (GLUE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leo Chandra P. | GLUE | Director | Mar 24 '25 | Buy | $5.84 | 10,000 | $58,383.00 | 10,000 |
Latest Monte Rosa Therapeutics Inc. News
GLUE Breaking Stock News: Dive into GLUE Ticker-Specific Updates for Smart Investing
GuruFocus.com
8 days ago
Monte Rosa Therapeutics Inc (GLUE) Q4 2024 Earnings Report Preview: What To Expect
Clinical Trials Arena
8 days ago
Mixed data results for two Monte Rosa molecular glue degraders
MT Newswires
8 days ago
Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $17 From $15, Maintains Outperform Rating
Zacks
9 days ago
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
MT Newswires
9 days ago
Monte Rosa Therapeutics Files $400 Million Mixed Shelf
GlobeNewswire
9 days ago
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
GlobeNewswire
18 days ago
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
Zacks
22 days ago
3 Top Cancer Biotechs to Keep An Eye On in 2025
Compare GLUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLUE Monte Rosa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.